Janney Montgomery Scott LLC Invests $897,000 in Health Catalyst, Inc. (NASDAQ:HCAT)

Janney Montgomery Scott LLC acquired a new stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 110,240 shares of the company’s stock, valued at approximately $897,000.

A number of other large investors also recently modified their holdings of HCAT. First Light Asset Management LLC grew its stake in shares of Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after purchasing an additional 3,221,408 shares in the last quarter. Millennium Management LLC boosted its position in Health Catalyst by 96.3% during the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after acquiring an additional 1,184,131 shares during the period. Primecap Management Co. CA boosted its stake in shares of Health Catalyst by 14.7% during the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after buying an additional 305,079 shares during the period. Daventry Group LP grew its stake in Health Catalyst by 3.9% in the second quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock valued at $14,359,000 after purchasing an additional 84,178 shares in the last quarter. Finally, Nepsis Inc. grew its position in Health Catalyst by 67.9% in the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after acquiring an additional 851,448 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Stock Performance

Shares of Health Catalyst stock opened at $7.65 on Friday. The firm has a market cap of $465.50 million, a price-to-earnings ratio of -5.67 and a beta of 1.32. Health Catalyst, Inc. has a one year low of $5.42 and a one year high of $11.41. The stock’s 50-day moving average is $8.16 and its 200-day moving average is $7.22. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.22) EPS. Equities analysts predict that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Insider Transactions at Health Catalyst

In other news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at approximately $1,062,018.64. This represents a 5.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This trade represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 34,068 shares of company stock worth $257,555. 2.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on HCAT. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Evercore ISI increased their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Stephens increased their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday. Royal Bank of Canada upped their target price on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Finally, Citigroup lifted their price target on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $11.71.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.